KTTA: Multiplikator P/S Pasithea Therapeutics
The venture potential of Pasithea Therapeutics (KTTA) is based on small molecule patents, as confirmed by the daily chart from the GURU.Markets service. The price-to-sales ratio, where the value 39.40 indicates the current figure, correlates with significant pricing power in the neurobiology segment. Strict FDA regulations and the high cost of clinical trials serve as business protections, creating a substantial barrier to entry for new players.
Rincian analitis perusahaan Pasithea Therapeutics (KTTA)
- kuotasi saiki lan rata-rata prakiraan nilai:
- informasi kapitalisasi pasar:
- data ekuitas miturut neraca:
- rincian struktur utang lan likuiditas bisnis:
Rasio Kabeh Utang marang Dana Pribadi Pasithea Therapeutics|KTTA - Utang jangka dawa marang modal|Kewajiban jangka cendhak marang modal pasitheaclinics.com|KTTA - Utang perusahaan|Rasio utang marang aset resik Pasithea|KTTA - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Pasithea Therapeutics|Rasio likuiditas kritis pasitheaclinics.com
- informasi bathi lan kelipatan valuasi:
KTTA - Bathi resik|Bathi resik sing dikarepake Pasithea Therapeutics|KTTA - Koefisien rega marang bathi|Pangali Forward P/E pasitheaclinics.com|KTTA - Pangali rega marang bathi tumrap wutah|Koefisien nilai perusahaan marang bathi operasional sadurunge panyusutan Pasithea|KTTA - Bathi operasional EBITDA|Bathi resik saben saham sajrone patang kuartal pungkasan Pasithea Therapeutics|KTTA - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan pasitheaclinics.com|KTTA - Wutah bathi saben saham ing taun lumaku|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep Pasithea Therapeutics
- indikator pendapatan dodolan lan penghasilan bisnis:
Analisis fundamental perusahaan:Pasithea Therapeutics Corp, KTTA
Maximum outsourcing of synthesis and testing at Pasithea Therapeutics (KTTA) minimizes capital expenditures by shifting operational risk to external contractors. The market capitalization-to-revenue ratio, represented by the fundamental P/S, allows investors to decouple price volatility from static sales, determining the premium paid for a business model with a lean management structure.
Perusahaan pesaing
BIIB - Rega marang dodolan|Multiplikator P/S NBIX (Neurocrine Biosciences, Inc.)|Multiplikator P/S Regencell Bioscience Ltd RGC|AXSM: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan ACAD (ACADIA Corp)|XENE (Xenon Pharmaceuticals) - Kapitalisasi marang pendapatan|VKTX: Kapitalisasi marang volume dodolan|SUPN (Supernus) - Multiplikator P/S|CPRX: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S DNLI|HRMY - Rega marang dodolan|Rasio rega marang pendapatan Biohaven Ltd. BHVN|Rasio kapitalisasi pasar marang pendapatan AMLX|Trevi Therapeutics, Inc. - Multiplikator P/S|PRAX - Multiplikator P/S|Anavex Corp (AVXL) - Rasio rega marang pendapatan|Rasio rega marang dodolan CBLL (CeriBell EEG)|PRTA (Prothena Biosciences) - Multiplikator P/S|Rega marang dodolan Alector Therapeutics ALEC|Kapitalisasi marang pendapatan ANNX (Annexon)|Multiplikator P/S omeros.com (OMER)|Neurogene Corp - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan ACIU (AC Immune Inc)|Voyager Therapeutics - Multiplikator P/S|Koefisien rega marang pendapatan neumoratx.com NMRA|SCLX: Multiplikator P/S|Kapitalisasi marang pendapatan Tevogen Bio Holdings Inc.|Rasio rega marang pendapatan Alpha Cognition Inc|Cognition Therapeutics Inc. (CGTX) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Inhibikase Therapeutics (IKT)|Multiplikator P/S cassavasciences.com (SAVA)|Assertio - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan COYA (Coya Therapeutics Inc)|VTGN: Kapitalisasi marang pendapatan|Ovid Therapeutics Inc. - Kapitalisasi marang volume dodolan|ABOS: Multiplikator P/S|cervomed.com (CRVO) - Multiplikator P/S|Rasio rega marang pendapatan Alterity Therapeutics Ltd.|Rasio kapitalisasi marang pendapatan CLNN (Clene Nanomedicine)|Multiplikator P/S PEPG|JUNS - Rega marang dodolan|Relmada Therapeutics - Kapitalisasi marang pendapatan|Multiplikator P/S annovisbio.com ANVS|GRCE - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan AIFF (Firefly Neuroscience, Inc.)|anewmeds.com (KLTO) - Rasio rega marang pendapatan|Rega marang dodolan NeuroSense Therapeutics Ltd. (NRSN)|Rasio rega marang pendapatan Reviva Pharmaceuticals|MetaVia, Inc. - Rasio rega marang dodolan|Multiplikator P/S NRXS|Multiplikator P/S heliusmedical.com (HSDT)|Rasio rega marang pendapatan Passage Bio PASG|Koefisien rega marang pendapatan Neuphoria Therapeutics, Inc. (NEUP)|Minerva Neurosciences - Multiplikator P/S|Koefisien rega marang pendapatan athira.com ATHA|ADXN (Addex Therapeutics Ltd) - Kapitalisasi marang pendapatan|ALZN: Kapitalisasi marang volume dodolan|CYCN (Cyclerion Therapeutics Inc.) - Multiplikator P/S|PTIX: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S CRGT|ATXI - Rega marang dodolan|Multiplikator P/S BCLI (BrainStorm Cell Therapeutics)|Multiplikator P/S Cara Therapeutics Inc. CARA|CHRO: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan ELYM (Eliem Therapeutics)|ITCI (intracellulartherapies.com) - Kapitalisasi marang pendapatan|LBPH: Kapitalisasi marang volume dodolan|MRNS (Marinus Pharmaceuticals, Inc.) - Multiplikator P/S|NKGN: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S NRBO|SAGE - Rega marang dodolan|Rasio rega marang pendapatan Synaptogenix, Inc. SNPX|Rasio kapitalisasi pasar marang pendapatan TRVN|Vigil Neuro - Multiplikator P/S|WENA - Multiplikator P/S|Cerevel (CERE) - Rasio rega marang pendapatan
